Statistically significant lower risk is seen for mortality, hospitalization, progression, and recovery. 9 studies from 7 independent teams (all from the same country) show significant improvements.
Meta analysis using the most serious outcome reported shows 64% [50‑74%] lower risk. Results are worse for Randomized Controlled Trials.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2, BA.4, BA.51, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.12. mAb use may create new variants that spread globally3,4, and may be associated with prolonged viral loads, clinical deterioration, and immune escape4-6.
No treatment or intervention is 100% effective. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective.
All data to reproduce this paper and sources are in the appendix.
Covid Analysis et al., May 2024, preprint, 1 author.